Comparative Pharmacology
Head-to-head clinical analysis: BETAXON versus CARTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAXON versus CARTROL.
BETAXON vs CARTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist; reduces intraocular pressure by decreasing aqueous humor production through inhibition of beta-1 receptors in the ciliary epithelium.
CARTROL is a beta-1 selective adrenergic receptor antagonist. It inhibits the effects of catecholamines on beta-1 receptors in the heart, reducing heart rate, myocardial contractility, and blood pressure.
0.25% ophthalmic solution, 1 drop in the affected eye(s) twice daily.
Adults: 2.5 mg orally twice daily, titrated up to maximum 10 mg twice daily.
None Documented
None Documented
Terminal elimination half-life is 12-18 hours; prolonged in renal impairment (up to 36 hours).
Terminal elimination half-life is 6–8 hours in normal renal function; prolonged to 20–40 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal (40-50% unchanged) and fecal (30-40% as metabolites); biliary excretion contributes minimally.
Primarily renal excretion (approx. 70% unchanged drug), with 20% biliary/fecal, and 10% metabolism to inactive metabolites.
Category C
Category C
Beta-Blocker
Beta-Blocker